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CD95 has long been viewed as a death receptor regulating apoptosis. In this issue of Immunity, Letellier et al.
(2010) tell us a different story, about the capability of CD95L to regulate leukocyte recruitment to sites of
inflammation.It is well established that the signaling pair
CD95L-CD95, also known as FASL-FAS,
signals to apoptosis in a variety of cellular
contexts. This paradigm has been re-
cently challenged by data showing that
CD95 may fulfill a range of physiological
nonapoptotic functions, including a role
as a proinflammatory mediator. In this
issue of Immunity, Letellier et al. (2010)
provide compelling evidence of the capa-
bility of CD95 to trigger signaling events
leading to leukocyte integrin-dependent
adhesion and migration and expand our
perception of the role of CD95 in nona-
poptotic functions.
CD95 is a prototypical member of the
tumor necrosis factor receptor super-
family containing an intracellular death
domain in its cytoplasmic tail, which trans-
mits a death signal to the cell (Strasser
et al., 2009). CD95 exists as a homotrimer
and is activated through binding to trimers
of its ligand CD95L (Siegel et al., 2000). In
the extrinsic (or death-receptor-regulated)
pathway, engagement of the death
receptor CD95 by CD95 ligand (CD95L)
leads to the activation of caspase 8 by
the adaptor protein FADD (FAS-associ-
ated death domain) and the formation of
the death-inducing signaling complex
(DISC) through homologous domain inter-
actions (Bouillet and O’Reilly, 2009).
Active caspase 8 then cleaves and acti-
vates caspase 3, caspase 6, and caspase7, which targets vital cellular substrates,
thus inducing cell death (Bouillet and
O’Reilly, 2009). The expression of CD95L
has to be carefully regulated to prevent
unintentional killing of healthy cells
because CD95 is widely expressed and
ligation of CD95 by CD95L potently trig-
gers apoptosis in many cell types (Bouillet
and O’Reilly, 2009).
It is largely accepted that several
members of the TNF-R family, including
some that are classified as death recep-
tors, and their corresponding ligands
exert non-apoptotic functions, such as
the induction of cellular activation, prolif-
eration, differentiation, or migration. By
applying an articulated experimental ap-
proach involving both animal models
and human subjects, Letellier et al. (2010)
investigated the involvement of CD95L as
a proinflammatory determinant in spinal
cord injury (SCI). The authors showed
that injury to the central nervous system
(CNS) increases CD95L surface expres-
sion on peripheral blood cells in rodents
and humans, thus establishing a potential
source for CD95L leading to CNS dam-
age. Specifically, neutrophils and macro-
phages were found to be the major source
of CD95L leading to CNS damage. Impor-
tantly, neutralization experiments and
gene expression analysis showed that
CNS damage is dependent on CD95L-
mediated proinflammatory activity andnot to direct CD95-induced apoptosis
of resident neural spinal cells, bringing
strong evidence for the role of CD95 in
nonapoptotic events. In particular, the
authors suggested that myeloid cells infil-
trate the lesion site in a CD95L-dependent
manner and produce proinflammatory
cytokines upon interaction with other im-
mune cells or with CNS-resident cells,
leading to the amplification of the immune
response. The authors further character-
ized the activity of CD95L-CD95 on leuko-
cyte function and find a role in regulation
of integrin-dependent adhesion and mi-
gration. CD95L also regulated cell recruit-
ment in a model of peritonitis, suggesting
that its involvement in leukocyte traf-
ficking is not restricted to the CNS. Inter-
estingly, the study by Letellier et al. (2010)
suggests that the interaction between
leukocyte-expressed CD95 and CD95L,
leading to enhanced migration and sub-
sequent tissue destruction, occurs in the
periphery before the migration of myeloid
cells in the target tissue. It is tempting to
speculate that pharmacological modula-
tion of CD95L-CD95 interaction may rep-
resent a potential therapeutic approach in
some inflammatory diseases.
The study by Letellier et al. (2010)
expands our view of death receptors and
definitively brings CDC95L-CD95 to the
realm of cell trafficking and inflammation.
This study also raises a number ofFebruary 26, 2010 ª2010 Elsevier Inc. 147
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Figure 1. CD95-Triggered Nonapoptotic
Signaling Pathway Leading to Adhesion
Activation and Migration in Myeloid Cells
Classically, CD95 activates a proapoptotic sig-
naling pathway leading to cell death. The findings
by Letellier et al. show that CD95 expressed on
myeloid cells (here represented by a polymorpho-
nuclear cell) may trigger a different signaling path-
way involving Src-family tyrosine kinases (SFKs),
Syk, PIP3K, and MMPs, leading to myeloid cell
adhesion to endothelial ligands belonging to the
immunoglobulin-like family, such as ICAM-1 or
VCAM-1, and recruitment to site of inflammation.
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Previewsinteresting questions for future investiga-
tion. For instance, it is not clear how
peripheral myeloid cells can ‘‘sense’’
distal tissue damage and upregulate
CD95L. Moreover, in the paper by Letellier
et al. (2010), a consistent body of results
was obtained with soluble CD95L, sug-
gesting that soluble CD95L, by interacting
with leukocyte-expressed CD95, is
responsible for myeloid cell activation in
periphery and enhanced migration to the
inflammatory site. However, further stud-
ies need to define whether CD95L acts
as a real chemoattractant, possibly gener-
ating itself a gradient in an autocrine or
paracrine fashion, or as a primer for
a subsequent chemotactic agonist gener-
ated within the damaged tissue. Notably,
till recently, although Fas-induced apo-
ptosis was known to require aggregation
of preassembled CD95 trimers (Siegel
et al., 2000), it was unclear whether mem-
brane-bound CD95L, soluble CD95L, or
both cause cell apoptosis. In addition,
it was also debated whether either or
both of these forms of CD95L have nona-
poptotic activities, such as induction of
inflammatory responses. Recent work by148 Immunity 32, February 26, 2010 ª2010 EO’Reilly et al. (2009) sheds light on these
uncertainties by demonstrating that
membrane-bound CD95L is essential for
cytotoxic activity and constitutes the
guardian against lymphadenopathy, auto-
immunity, and cancer, whereas increased
soluble FasL has nonapoptotic proinflam-
matory effects and appears to promote
autoimmunity and tumorigenesis (O’Reilly
et al., 2009). Taking into account these
recent findings, the data by Letellier et al.
(2010) published in this issue suggest
that the soluble form of CD95L may repre-
sent an agonist generating intracellular
signals leading to myeloid cell migration.
The emerging picture suggests a role for
soluble CD95L in leukocyte migration, as
well as in MAP kinase and NF-kB pathway
activation, with consequent stimulation of
cell proliferation, survival, and cytokine
production. However, future studies are
required to better characterize the role of
soluble versus membrane-bound CD95L
during immune responses.
Signal transduction pathwaysgenerated
by CD95 and leading to apoptosis or non-
apoptotic events have been investigated
in the last years. From previous studies,
performed in vitro and in vivo, FADD, cas-
pase-8, and c-FLIP (components of DISC)
are known to link CD95 to nonapoptotic
pathways (Peter et al., 2007). Neverthe-
less, how FADD and caspase-8 are acti-
vated during CD95-induced nonapoptotic
events and what intracellular nonapoptotic
signaling pathways are triggered by cas-
pase-8 are currently unresolved questions
(Strasser et al., 2009). The paper by Letel-
lier et al. (2010) investigated the signaling
mechanisms triggered by CD95L leading
to myeloid cell migration. The authors
extended their previous observations
showing that CD95L triggers invasion
of glioblastoma cells and differentiation of
adult neural stem cells via activation of
Src tyrosine kinases and PI3K (phosphati-
dylinositol-3-kinase). They further showed
that stimulation of CD95 with soluble
CD95L on myeloid cells contributes to
migration by triggering Syk tyrosine kinase
activity. CD95L-dependent Syk phosphor-
ylation seems to be triggered by Lyn, a
member of Src tyrosine kinase family.
Moreover, the authors showed that Syk
phosphorylation leads to the activation of
PI3K, a molecule that has been shown to
link G-coupled protein receptors (GPCR)
to integrin-dependent adhesion (Constan-
tin et al., 2000). Thus, CD95 death receptorlsevier Inc.activates migration through a signaling
cascade involving Src, Syk, and PI3K
and, as previously shown for glioblastoma
cells, includes activation of metalloprotei-
nase (MMP)-2 and -9 as well (Letellier
et al., 2010) (Figure 1).
The signaling mechanisms described in
the paper by Letellier et al. (2010) raise
questions about integrin triggering and
adhesion. In recent years, the signaling
events leading to integrin activation have
been the focus of intense investigation. It
is now well established that activation of
integrin-dependent adhesion should not
be considered as just a single phenom-
enon, but more likely as a group of highly
coordinated cellular events globally lead-
ing to leukocyte recruitment to the blood
vessels (Ley et al., 2007). These events
are finely tuned by specific intracellular
signaling mechanisms triggered by che-
moattractants, each one devoted to con-
trolling specific aspects of the adhesion
process (Constantin et al., 2000; Lau-
danna and Alon, 2006). The most charac-
terized pro-adhesive signaling mecha-
nisms regard the function of Ras and
Rho small-GTP binding proteins, namely
Rap1 and the recently discovered Rho-
module (Bolomini-Vittori et al., 2009).
Overall, it appears that integrin activation
is controlled by modular signaling net-
works controlling the various aspects of
integrin activation, including constraint
removal, affinity, clustering, and postbind-
ing stabilization. In this context, the role of
protein tyrosine kinases is still not well
defined. Thus, the data presented in this
issue by Letellier et al. (2010) clearly high-
light the possibility of an involvement of
Syk in signaling triggered by proadhesive
agonists and possibly leading to Rap1
and rho-small GTPase activation, thus
controlling integrin triggering. This rele-
vant aspect needs to be investigated in
future studies. Furthermore, it will be inter-
esting to characterize whether CD95L
may also act as a direct agonist of integrin
affinity triggering, thus suggesting its role
in cell arrest under flow, a condition that
was not explored by Letellier and
colleagues.
Overall, the study by Letellier and
colleagues, by linking CD95 (FAS) death
receptor to leukocyte trafficking, further
emphasizes the relevance of nonapop-
totic functions of CD95 and characterizes
the signaling machinery controlling CD95
involvement in nonapoptotic events.
Immunity
PreviewsThese studies potentially provide new tar-
gets to treat diseases, such as inflamma-
tion and cancer, for which nonapoptotic
activities of CD95 are proving important
(Peter et al., 2007).
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In this issue of Immunity, Luber et al. (2010) report a comprehensive quantitative proteome of in vivo mouse
spleen dendritic cell (DC) subsets: a data set of encyclopedic value already revealing that DC subsets exploit
different RNA sensors for virus recognition.Denditic cells (DCs) are key players in the
immune response against invading patho-
gens and provide a direct link between
inate and adaptive immune responses.
As antigen-presenting cells, DCs are able
to recognize, take up, and process patho-
gens, dying cells, and malignant cells into
antigenic fragments that are subsequently
presented on major histocompatibility
complexes to T cells to initiate adaptive
immune responses.
In recent years it has become clear that
DCs do not represent one homogeneous
population of antigen-presenting cells
but rather form a plethora of distinct sub-
types, defined by specific cell-surface
markers. For some subsets, specialized
immune functions have been recognized
(Shortman et al., 2009). For example in
mice, CD8a+ spleen DCs were recognized
as most efficient in cross-presentation
of antigens derived from dying cells
in MHC class I, a function less well
performed by other CD8a DC spleensubsets. Although CD8a is not expressed
by human DCs, BDCA3+ blood DCs
might represent the human counterpart.
Furthermore, plasmacytoid DCs, a subset
present both in mice and men, are known
to master the initiation of antiviral immune
responses by secretion of large amounts
of type I interferons. However, in spite of
all efforts to elucidate the nature of these
phenotypically defined subsets, func-
tional differences as well as the relation
between subsets in the human and the
murine system are still incompletely
resolved.
Murine splenic DCs are certainly the
most widely studied cells in DC biology.
At steady state, two major DC subsets
can be distinguished: conventional DCs
(cDCs) and plasmacytoid DCs (pDCs).
Spleen cDCs can be further subdivided
into CD8a+CD4 DCs, CD8aCD4+ DCs,
and CD8a CD4 double negative (DN)
DCs. Thus far, mainly comparative micro-
array studies have been performed inattempts to elucidate functional speciali-
zations in these splenic subsets (Robbins
et al., 2008). RNA expression, however,
does not necessarily predict protein
abundance. Transcripts can be transla-
tional nonactive, RNA and protein may
differ in stability, or protein expression
can be controlled by posttranslational
modifications rather than at a transcrip-
tional level.
In this issue of Immunity, Luber et al.
(2010) use their long-standing expertise
in proteomics to gain more insight in the
differences that exist between these
mouse spleen DC subsets. This was not
an easy task given that the quantitative
comparison of such rare cell populations
in vivo by proteomics was until now
greatly hampered by the lack of tech-
nology and the large costs involved,
especially when taking into account the
number of biological replicates required
for statistical significance. Novel algo-
rithms were developed for label-freeFebruary 26, 2010 ª2010 Elsevier Inc. 149
